Seattle, WA, August 16, 2024 –Blink Device Company announces the launch of the TwitchView®2 System, the second generation of its electromyographic (EMG) quantitative neuromuscular monitoring system redesigned for improved reliability, performance, and ease-of-use. Upgrades include a ruggedized housing, an EMG algorithm with increased sensitivity, a streamlined user interface, strengthened EMR connectivity, the introduction of universal mounting solutions, and three redesigned electrodes.
The first TwitchView System received 510(k) clearance in 2018. Leveraging thousands of hours of real-world experience and feedback from early adopters, Blink’s team of engineers, medical scientists, regulatory, and medical device experts refined, retested, and enhanced every aspect of the original TwitchView System to develop TwitchView2.
CEO, Justin Hulvershorn MD, PhD commented:
“At Blink, our sole focus is developing quantitative neuromuscular monitors that clinicians trust and want to use. Experts have demonstrated that they are able to eliminate residual neuromuscular blockade and facilitate spontaneous recovery without pharmacologic reversal in 20% of patients when using TwitchView. This not only enhances patient safety but also reduces unnecessary hospital expenses. We’re introducing the TwitchView2 System to make these results even easier to replicate in routine clinical practice.”